Document Detail


Attendance versus compliance with tuberculosis treatment in an occupational setting--a pilot study.
MedLine Citation:
PMID:  9472274     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To determine the prevalence of non-compliance with tuberculosis treatment at Freegold Mines.
OBJECTIVES: 1. To establish the rates of attendance and collection of anti-tuberculosis drugs. 2. To determine prevalence of non-compliance by means of urine tests.
DESIGN: A cross-sectional study conducted over 2 weeks at mine medical stations.
METHOD: Urine samples were collected from tuberculosis patients 3 hours after drug ingestion. Non-compliance was established by testing these samples for rifampicin and/or isoniazid (INH) metabolites. Non-compliance was defined as a negative urine test result for these drugs in participants whose treatment regimens included one or both. Daily attendance and collection of drugs statistics are recorded in the medical station tuberculosis register. The patient rate of adherence was calculated as the observed number of days on which medication had been collected over the expected treatment days in a given period.
RESULTS: Urine test results showed an overall prevalence of non-compliance of 14.6 +/- 3.3%. The study showed that non-compliance with tuberculosis treatment was underestimated by the surveillance data. The rate of non-adherence with treatment established from the formal surveillance procedure was 0.2%. The poor response rate of patients was found to be a major problem and fewer than 40% per day returned to bring urine specimens. The mean prevalences of non-compliance established by rifampicin and INH tests were 19.5 +/- 5.3% and 9.8 +/- 3.9%, respectively, and these were significantly different (Chi 2 = 7.44; P < 0.05). The proportion of false-positive results for INH and rifampicin urine tests were 21% (11/53) and 35% (17/48), respectively, showing that some patients were taking the wrong treatment.
CONCLUSIONS: It is clear that attendance at the clinics does not accurately reflect compliance. Both programme compliance (dispensing of the correct treatment) and patient compliance need to be improved. This has important implications for the new national tuberculosis control policy adopted by the South African government that stresses the importance of directly observed therapy, short-course (DOTS) and a patient-centred approach.
Authors:
N P Mqoqi; G A Churchyard; I Kleinschmidt; B Williams
Related Documents :
19910234 - Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary asperg...
20980204 - Comparison of knowledge on travel related health risks and their prevention among human...
18444974 - The use of glucan as immunostimulant in the treatment of a severe case of chromoblastom...
6762044 - Acyclovir and idoxiuridine treatment of herpes simplex keratitis--a double blind clinic...
17189804 - Factors influencing refractive outcomes after combined phacoemulsification and pars pla...
1169134 - Operative treatment in hypertrophic subaortic stenosis. techniques, and the results of ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde     Volume:  87     ISSN:  0038-2469     ISO Abbreviation:  S. Afr. Med. J.     Publication Date:  1997 Nov 
Date Detail:
Created Date:  1998-03-18     Completed Date:  1998-03-18     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  0404520     Medline TA:  S Afr Med J     Country:  SOUTH AFRICA    
Other Details:
Languages:  eng     Pagination:  1517-21     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibiotics, Antitubercular / therapeutic use*,  urine
Chi-Square Distribution
Cross-Sectional Studies
Drug Monitoring / methods
False Positive Reactions
Gold
Humans
Isoniazid / therapeutic use*,  urine
Mining*
Patient Compliance*
Pilot Projects
Prevalence
Rifampin / therapeutic use*,  urine
South Africa
Tuberculosis, Pulmonary / drug therapy*
Chemical
Reg. No./Substance:
0/Antibiotics, Antitubercular; 7440-57-5/Gold; V83O1VOZ8L/Isoniazid; VJT6J7R4TR/Rifampin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Resisting constraints, creating opportunities. The experiences of some early medical women.
Next Document:  Field evaluation of a novel haemoglobin measuring device designed for use in a rural setting.